The Philadelphia-based company engineered a viral capsid that achieved significantly improved tissue targeting in primates.
Live Poll
Are you optimistic that advances in gene therapy will successfully treat complex kidney diseases?
September 29, 2026
Aro Biotherapeutics Appointed Brett Blackman to BoardThe Philadelphia-based biotech company added the veteran executive to its leadership team to support growth.
September 28, 2026
Tolerance Bio Licensed Anti-IL-33 Drug From Tanabe PharmaThe Philadelphia-based company secured global rights, excluding Japan, to advance the drug toward Phase 2 trials.
September 23, 2026
Pharma Leaders Gathered in PhiladelphiaThe event drew over 3,500 industry professionals to the Pennsylvania Convention Center for a four-day conference.
September 19, 2026
Latus Bio Appointed New Board MembersThe Philadelphia-based biotech firm added two experienced executives to help oversee its transition to clinical-stage work.
